EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY-NC 4.0

Tocilizumab for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: A matched case-control retrospective study

Bingpeng Guo iD, Junfeng Huang, Gengjia Chen, Xilai Chen, Du Feng, Hao Deng iD, Xinxian Lan, Yu Deng, Qun Luo, Qian Han

Therapeutic Advances in Respiratory Disease · 2026-08 · 20

DOI: 10.1177/17534666261480225 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 20.08.2026. Verfasst von Bingpeng Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Na…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Idiopathic Pulmonary Fibrosis, Methylprednisolone, Glucocorticoids. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Noncommunicable Chronic Diseases and National Science and Technology Major Project, Guangzhou Health Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a lethal condition with mortality exceeding 50% at 3 months, driven by hyperinflammation. Elevated interleukin-6 (IL-6) is associated with poor outcomes. Tocilizumab (TCZ), an IL-6 receptor antagonist, may modulate this harmful inflammation.

Objectives

To evaluate the efficacy and safety of tocilizumab combined with corticosteroids in AE-IPF.

Design

Retrospective, propensity score-matched, case-control study.

Methods

Thirty-nine AE-IPF patients from a registry (NCT03666234) were included. Thirteen received tocilizumab (8 mg/kg) plus methylprednisolone, matched 1:2 to 26 receiving conventional therapy. The primary outcome was 3-month all-cause mortality or lung transplantation. Secondary outcomes included changes in ground-glass opacity (GGO) scores and inflammatory biomarkers.

Results

Baseline characteristics were balanced. A GGO score ≥18 predicted higher mortality (HR 5.01, 95% CI 1.47–17.14; p=0.01). In univariable analysis, TCZ was associated with a lower but non-significant risk of the 90-day composite endpoint compared with conventional therapy (unadjusted HR 0.39, 95% CI 0.13–1.18; p=0.095). In an exploratory multivariable Cox model adjusting for baseline GGO score and inflammatory markers, TCZ was associated with a significant risk reduction (adjusted HR 0.20, 95% CI 0.05–0.72; p=0.014). In exploratory subgroup analyses, TCZ was associated with marked risk reductions in high-risk subgroups: GGO score ≥18 (HR 0.07, 95% CI 0.01–0.36; p=0.002), moderate oxygenation impairment (HR 0.12, 95% CI 0.02–1.00; p=0.05), and elevated inflammatory markers (HR 0.26, 95% CI 0.08–0.82; p=0.021). Tocilizumab also reduced GGO scores (p=0.009). Severe infections occurred in 23.1% (3/13) of the tocilizumab group between post-treatment days 12 and 30.

Conclusion

In this small, propensity-matched cohort, while the primary unadjusted analysis did not reach statistical significance, multivariable adjustment revealed a significant survival benefit signal associated with TCZ, particularly in patients with extensive ground-glass opacities or hyperinflammation. These findings suggest that TCZ may offer clinical advantages for specific high-risk AE-IPF subgroups, warranting validation in larger prospective trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedIdiopathic Pulmonary FibrosisMethylprednisoloneGlucocorticoidsAnti-Inflammatory AgentsHumansFemaleRetrospective StudiesMaleTreatment OutcomeDisease ProgressionCase-Control StudiesAgedDrug Therapy, CombinationMiddle AgedTime FactorsReceptors, Interleukin-6RegistriesPropensity Score

Stichwörter der Autor:innen

acute exacerbationidiopathic pulmonary fibrosistocilizumab

Substanzen

Antibodies, Monoclonal, HumanizedtocilizumabMethylprednisoloneReceptors, Interleukin-6GlucocorticoidsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital…
  • Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Nanshan School, Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Pulmonary and Critical Care Medicine, Huizhou Third People's Hospital, Guangzhou Medical University, Huizhou, China.

ORCID-Profile: Bingpeng Guo, Hao Deng

Förderung

  • Noncommunicable Chronic Diseases and National Science and Technology Major Project
  • Guangzhou Health Science and Technology Project

Zitieren

APA

Guo, B., Huang, J., Chen, G., Chen, X., Feng, D., Deng, H., Lan, X., Deng, Y., Luo, Q., & Han, Q. (2026). Tocilizumab for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: A matched case-control retrospective study. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261480225

Vancouver

Guo B, Huang J, Chen G, Chen X, Feng D, Deng H, et al. Tocilizumab for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: A matched case-control retrospective study. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261480225

BibTeX
@article{Guo2026,
  author = {Guo, Bingpeng and Huang, Junfeng and Chen, Gengjia and Chen, Xilai and Feng, Du and Deng, Hao and Lan, Xinxian and Deng, Yu and Luo, Qun and Han, Qian},
  title = {Tocilizumab for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: A matched case-control retrospective study},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  volume = {20},
  doi = {10.1177/17534666261480225}
}
Kostenlos starten →